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Abstract: Residual coronary heart disease remains a significant problem even after adequate 
statin therapy for cardiovascular risk reduction as currently recommended by the Adult Treatment 
Panel III (ATP-III) of the National Cholesterol Education Program (NCEP). This is particularly 
true for the high risk patients as defined by ATP-III that includes those patients who have a 
greater than 20% 10-year risk of adverse cardiac events. For such patients the current goal of 
a low-density lipoprotein cholesterol (LDL-cholesterol) maintenance level of 100 mg/dL 
plasma appears to be suboptimal. Accumulating data from several recent randomized studies of 
more aggressive LDL-cholesterol reduction to levels below 70 mg/dL in the high risk patients 
favor acceptance of such a new lower target for LDL-cholesterol using more intensive statin 
therapy which would affect the treatment strategy for patients with coronary heart disease pre-
percutaneous intervention, metabolic syndrome, diabetes mellitus, congestive heart failure, 
cerebro-vascular disease and chronic kidney disease.
Keywords: statins, high risk patients, dyslipidemia, intensive statin therapy, metabolic 
syndrome, diabetes, congestive heart failure, chronic kidney disease, coronary atherosclerosis, 
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Introduction
Cardiovascular disease (CVD) continues to be the leading cause of mortality and 
morbidity in the United States. The cost of CVD care surpassed US$450 billion in 2008 
according to the National Heart, Lung, and Blood Institute (NHLBI). Although the strat-
egy of aggressively lowering the low-density lipoprotein cholesterol (LDL-cholesterol) 
with statins has significantly decreased the cardiac events, a substantial number of CVD 
events still occur, as seen in the majority of trials of aggressive versus standard statin 
therapy. This is especially true for the patients who are generally classified as being high 
risk according to the National Cholesterol Education Program (NCEP) Adult Treatment 
Panel III (ATP III). Several randomized trials have evaluated increasingly aggressive 
lipid-lowering therapy in these patients, and therefore the lipid treatment strategy needs 
to go beyond the current recommendation for the high risk patients. Institution of very 
aggressive secondary prevention strategy, and aggressive reduction of LDL-cholesterol 
levels to below 70 mg/dL, are rightly recommended for the very high risk patients. This 
group includes patients with coronary heart disease (CHD) and presentation with acute 
myocardial infarction (AMI) or acute coronary syndromes (ACS) as per the 2004 update 
of the initial 2001 NCEP-ATP III report. However, these recommendations fall short of 
addressing a variety of CHD patients at high risk who continue to exhibit an acceptable 
level of residual risk for recurrent acute coronary events. Several recent trials, such as Vascular Health and Risk Management 2009:5 496
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the Treating to New Targets (TNT) trial, the Collaborative 
Atorvastatin Diabetes Study (CARDS), the Stroke Prevention 
by Aggressive Reduction in Cholesterol Levels (SPARCL), 
and the Lipid-Lowering Arm of the Anglo-Scandinavian 
Cardiac Outcomes Study (ASCOT-LLA) trial, lend support 
to the idea that greater LDL-cholesterol lowering than that 
achieved with standard dose of statins may be warranted in 
high risk patients as well. Such evidence-based studies in 
high risk patients supporting the use of high dose statins are 
discussed in this review.
High risk patients
High risk patients are defined as those who already have had 
manifest CHD or CHD equivalents, such as diabetes mellitus 
(DM), peripheral vascular disease (PVD), cerebrovascular 
disease (C-VD), or abdominal aortic aneurysm (Figure 1).1 
Chronic kidney disease (CKD) is also considered a CHD 
equivalent condition by some authors. These patients have 
greater than 20% 10-year risk of acute cardiac events accord-
ing to the Framingham Heart Study risk score calculations. 
Patients with features of metabolic syndrome (MS) exhibit 
similar high risk prognosis. In addition, patients present-
ing with acute coronary syndrome (ACS), or those pre-
percutaneous intervention (pre-PCI), also form a group of 
high risk patients who appear to derive greater benefit with 
increasingly more aggressive statin therapy and reduction of 
LDL-cholesterol to ∼70 mg/dL range.
Institution of similar aggressive treatment strategy for 
these high risk patients as has been recommended for the 
very high risk group was recently studied in a randomized 
clinical trial called the Treating to New Targets (TNT) trial 
that randomized 10,001 patients. It unequivocally showed 
that for these high risk patients, an additional highly aggres-
sive reduction of LDL-cholesterol level to under 70 mg/dL 
through the use of a high dose of atorvastatin (80 mg daily) 
did decrease the cardiac risk even more significantly than 
the current strategy of moderate LDL-cholesterol reduction 
to a level just below100 mg/dL generally achievable with 
low dose of atorvastatin (10 mg daily). In the Scandinavian 
Simvastatin Survival Study (4S) with 5 years of follow-up, 
twice as much risk reduction was seen in the patients with 
diabetes as in those without diabetes. These and other similar 
studies are reviewed in detail below.
Trials of aggressive statin therapy
Ever since the introduction of statin agents for the treatment 
of hypercholesterolemia for reduction of CHD, increasingly 
more aggressive treatment has, over the years, shown increas-
ingly more significant proportionat benefit. The target LDL-
cholesterol has continued to slide down to lower levels as more 
evidence has accumulated through the randomized trials of the 
past decade. In the Pravastatin and Atorvastatin Evaluation and 
Infection Therapy (PROVE-IT TIMI 32) study, much more 
aggressive reduction of LDL than recommended by NCEP-
0
2
4
6
8
10
12
14
16
18
20
4 yrs
Atorva-80
Atorva-10
p = 0.026 
HR = 0.75 
(CI 0.58, 0.79) 
Percentage of
patients
with major
cardiovascular
events
6 yrs
Figure 1 Kaplan-Meier estimates of the incidence of major cardiovascular events in patients with diabetes mellitus (includes congestive heart failure death, non-fatal non-
procedure-related acute myocardial infarction, resuscitated cardiac arrest, and fatal or non-fatal stroke).
Abbreviations: HR, hazard ratio; CI, confidence interval.Vascular Health and Risk Management 2009:5 497
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ATP III guidelines was undertaken using high dose statins, 
and increasingly greater reduction in cardiovascular events 
was observed in the patients with CHD who presented with 
ACS/non-ST-elevation myocardial infarction (NSTEMI).2 
The LDL-cholesterol level decreased to 62 mg/dL in the 
patients who took a high dose of atorvastatin (80 mg daily) 
compared with those who took simvastatin (40 mg daily). The 
LDL-cholesterol level in the simvastatin group was reduced 
to only ∼95 mg/dL. Even though this level was consistent 
with NCEP recommendations, the atorvastatin group with 
more aggressive LDL reduction showed an additional ∼25% 
decrease in the cardiovascular event rate. The Heart Protec-
tion Study (HPS) exhibited similar results in all participants, 
including the subjects whose baseline LDL-cholesterol level 
was under 100 mg/dL, and who were treated with simvastatin.3 
The treated subgroup showed a significantly lower event 
rate of 16.4% than the placebo group, at 21%. Following the 
release of the data from these studies, the NCEP-ATP III panel 
met in 2004, and updated its 2001-guidelines by adding an 
optional LDL goal of 70 mg/dl for CHD patients who fell in 
the “very high risk” category, such as the patients who present 
with AMI or ACS/NSTEMI).1,4 For all other CHD patients or 
those with CHD “risk equivalent” features the recommended 
LDL target level is still 100 mg/dL. It should be noted that 
these patients consistently continue to exhibit a “high” 
(20%) 10-year risk as predicted by the Framingham Risk 
score tables for both men and women. Such a high residual 
risk and recurrent event rate should be unacceptable, and 
strategies must be developed to decrease this risk.
Over the past several years, new trials have generated a 
wealth of evidence supporting a new strategy for increas-
ingly aggressive risk reduction even in the yet neglected 
subgroup of non-acute CHD patients who are at higher risk 
because of the presence of multiple risk factors, and who, 
too, may benefit from more intense LDL-cholesterol reduc-
tion. The TNT trial randomized 10,001 patients with stable 
CHD and baseline LDL-cholesterol level under 130 mg/dL 
into two groups – first, an aggressive strategy group, to 
be treated with high dose atorvastatin (80 mg/day) with 
goal LDL  70 mg/dL)) and the other, a moderate strategy 
group, to be treated with regular dose atorvastatin (10 mg 
per day) with goal LDL-cholesterol 100 mg/dL.5 After a 
5-year follow up, the results from the TNT study convinc-
ingly exhibited an additional ∼35% decrease in the level of 
LDL-cholesterol and a proportionate reduction in cardiac 
event rate in the aggressive strategy cohort compared with 
the moderate strategy cohort. Subsequent examination of 
various subgroups, such as those with DM, MS, congestive 
heart failure (CHF), and renal insufficiency, unequivocally 
showed statistically significant additional event reduction 
in the aggressive LDL-cholesterol treatment group (goal: 
62 mg/dL with 80 mg of atorvastatin daily) over and above 
the currently recommended 100 mg/dL LDL-cholesterol 
level generally achievable with 10 mg of atorvastatin daily.6–9 
Several other trials have recently added more evidence to the 
literature demonstrating similar benefit of increasingly aggres-
sive reduction in the level of LDL-cholesterol even in patients 
with average baseline cholesterol levels who do not yet have 
manifest CHD, but are at a relatively higher risk owing to the 
concomitant presence of risk factors. ASCOT-LLA showed 
reliable evidence for the use of statins in patients with so-called 
normal cholesterol levels who have hypertension and three 
other additional cardiac risk factors.51 In CARDS, primary 
prevention of cardiovascular events with 10 mg of atorvas-
tatin daily was undertaken in patients with type 2 diabetes but 
without manifest CHD.50 High dose atorvastatin was shown 
to be safe and significantly effective in decreasing the risk of 
cardiovascular events, including stroke. Furthermore, in the 
SPARCL trial, atorvastatin given as 80 mg daily to patients 
with history of prior stroke or transient ischemic attack (TIA) 
but with normal cholesterol levels and without CHD resulted 
in significant improvement in the clinical outcomes. 52
Thus, it has now become abundantly clear from these 
randomized trials that there now exists an evidence-base 
supporting the clinical indications for high dose atorvastatin 
for treating high risk patients. Such increasingly aggressive 
Table 1 Goals and end points for lipid-lowering therapy (modified from NCEP ATP III recommendations)
Risk level High risk Intermediate risk Low risk
Number of risk factors CHD, CHD risk equivalents 2 risk factors 0–1 risk factors
10-year risk 20% 10%–20% 10%
Target LDL-cholesterol level (mg/dL) 100 
70 (very high risk)
130 160
end point for initiating drug therapy 130 160 190
Abbreviations: CHD, congestive heart failure; LDL-cholesterol, low-density lipoprotein cholesterol.Vascular Health and Risk Management 2009:5 498
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LDL-cholesterol reduction as part of a secondary prevention 
strategy in patients with already diagnosed CHD, and for 
primary prevention in patients with various risk factors 
including DM, MS, CHF and renal insufficiency, appears to 
be the next step in decreasing the cardiac risk even further. 
We will now review and discuss the evidence-based data 
from such randomized studies in CHD and CHD equivalent 
conditions that constitute the high risk patients.
Diabetes mellitus (DM)
Patients with DM are considered high risk since DM con-
stitutes a CHD equivalent condition as described in the 
NCEP-ATP III report.4 According to the Framingham risk 
score calculations, patients with adult-onset diabetes, even 
those without clinically manifest CHD, fall in the high risk 
category with a 20% 10-year risk for recurrent or adverse 
coronary events.28,29 Diabetics who experience an AMI fair 
worse than non-diabetic patients.30 A major underlying risk 
factor in diabetes patients is the atherogenic dyslipidemia 
generally manifested by high triglyceride, low values for 
high-density lipoprotein cholesterol (HDL-cholesterol), and 
an abundance of smaller, denser, and highly atherogenic LDL 
particles.31 Lowering the elevated level of LDL-cholesterol 
with statins to the current goal of 100 mg/dL causes sig-
nificant reductions in cardiovascular events in patients with 
diabetes and CHD.32,33 However, high residual risk persists. 
Newer studies suggest the need for further lowering the goal 
LDL-cholesterol level for patients with CHD who have high 
risk co-morbidities.1,2 DM is one such co-morbid state. While 
the American Diabetes Association (ADA) still recommends 
an LDL-cholesterol target of 100 mg/dL, the potential 
for a more aggressive LDL-cholesterol reduction to a goal 
level of 70 mg/dL may be additionally beneficial.34 The 
recently concluded TNT study supports such a strategy for 
diabetic patients. In this trial increasingly aggressive LDL-
cholesterol reduction in patients with established CHD was 
evaluated in a randomized fashion.5 Decrement of the mean 
LDL-cholesterol level to approximately 77 mg/dL using 
80 mg of atorvastatin daily resulted in additional 22% risk 
reduction compared with the currently recommended strat-
egy involving decrement to a mean LDL-cholesterol level 
of about 101 mg/dL using 10 mg of atorvastatin per day.27 
Further sub-analysis of the diabetic patients in the TNT study 
was carried out to see whether similar magnitude of clinical 
benefits of lowering LDL-cholesterol levels to new levels 
below what is currently recommended can be achieved, and 
whether that would translate into actual improvement in the 
clinical outcome. This sub-analysis included 1501 diabetic 
patients with mean LDL-cholesterol levels of 130 mg/dL, 
who had been randomized to double-blind therapy with either 
high dose atorvastatin ( 80 mg daily, n = 748) or low dose 
atorvastatin (10 mg daily, n = 753) and followed for 4.9 years. 
Primary end point of the TNT study included the time to first 
major cardiovascular event (ie, CHD death, non-fatal AMI, 
cardiac arrest, or stroke. The final mean LDL-cholesterol 
level was 98.6 mg/dL in the low dose atorvastatin group 
and 77.0 mg/dL with high dose atorvastatin. The primary 
end point was seen in 17.9% patients receiving atorvastatin 
10 mg, compared with 13.8% receiving atorvastatin 80 mg 
(hazard ratio [HR] 0.75 [95% CI 0.58 –0.97], p = 0.026). 
This translated to a 25% reduction in the risk of major car-
diovascular events in support of the high-dose strategy (HR 
0.75 [95% CI 0.58–0.97], p = 0.026) (Figure 1). Significant 
event reduction was observed in the high dose atorvastatin 
cohort as compared with the low dose atorvastatin group 
across all quintiles of age, duration of diabetes, and low or 
high HbA1c (HbA1c  7% or 7%, respectively). Further-
more, a significant event reduction in the group on high dose 
atorvastatin was also seen for time to cerebro-vascular event 
or TIA (0.69 [0.48–0.98], p = 0.037) and any cardiovascular 
event (0.85 [0.73–1.00], p = 0.044). There was, however, 
no significant difference observed between the two groups 
for all cause mortality. Out of the 8,500 patients without 
the diagnosis of diabetes at initial screening, 865 patients 
(10.2%) developed DM during the course of the study – 425 
in the 10-mg atorvastatin cohort and 440 in the high dose 
atorvastatin group (odds ratio 1.04, p = 0.59). Thus, the 
data from the TNT sub-analysis demonstrate that lowering 
the LDL-cholesterol with high dose atorvastatin therapy to 
levels well below 100 mg/dL is safe. It showed no significant 
increase in adverse events among patients with diabetes and 
CHD who were on high dose atorvastatin compared with the 
low dose atorvastatin group. For example, among the diabetes 
patients, the overall adverse event rate was 7.0% in the high 
dose atorvastatin group and 5.4% in the low dose group. The 
incidence of myalgia was 2.4% and 3.6% in the high dose 
and low dose cohorts respectively, and the difference was 
not statistically significant. Persistent elevations in alanine 
aminotransferase (ALT) and/or aspartate aminotransferase 
(AST) above the 3 times the upper limit of normal were seen 
in 0.9% of patients receiving 80 mg of atorvastatin daily and 
in 0.4% in those receiving 10 mg of atorvastatin daily (p = ns). 
No incidents of rhabdomyolysis were encountered.
Similarly, a subgroup analysis of the 4S study indicated 
that cholesterol lowering with simvastatin improves prog-
nosis in diabetic patients with CHD.32 An analysis of the Vascular Health and Risk Management 2009:5 499
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202 diabetic patients and 4242 non-diabetic patients with 
previous MI or angina pectoris, and raised serum cholesterol 
level, was performed and the findings were compared. At the 
end of the 5.4-year median follow-up, while the simvastatin-
treated group showed similar mean changes in serum lipids 
in diabetic and non-diabetic patients, the relative risk (RR) 
of the principal endpoints in the simvastatin-treated diabetic 
patients was significantly lower. The risk ratio for total mor-
tality was 0.57 (95% CI, 0.30–1.08; p = 0.087), for major 
coronary events 0.45 (95% CI, 0.27–0.74; p = 0.002), and 
that for any atherosclerotic event 0.63 (95% CI, 0.43–0.92; 
p = 0.018). The corresponding RRs in non-diabetic patients 
were 0.71 (95% CI, 0.58–0.87; p = 0.001), 0.68 (95% CI, 
0.60–0.77; p  0.0001), and 0.74 (95% CI, 0.68–0.82; 
p  0.0001), respectively. These results indicate that the 
absolute clinical benefit achieved by cholesterol lowering 
may be greater in diabetic than in non-diabetic patients 
with CHD because diabetic patients have a higher absolute 
risk of recurrent coronary events and other atherosclerotic 
events to begin with. The ADA, in 2005, updated the clinical 
practice recommendations for the diabetics with CHD, with 
clear emphasis on the fact that diabetic patients are at very 
high risk for future clinical events.34 On the basis of the data 
from the randomized trials of moderate versus aggressive 
lipid lowering in populations at very high risk, the ADA 
now recommends the use of high dose statins for reducing 
the LDL-cholesterol to a new goal, ie, under 70 mg/dL as a 
therapeutic option.1,5,27,35 The analysis of the diabetic patients 
in the TNT study also provides strong evidence of significant 
cardiovascular risk reduction with high dose statin therapy 
irrespective of their initial LDL-cholesterol level, age, dura-
tion of diabetes, or the intensity of glycemic control when 
compared with low dose treatment.
A primary prevention strategy of cardiovascular risk 
reduction with atorvastatin was studied in the CARDS trial, 
involving patients with adult-onset diabetes mellitus who had 
normal levels of baseline LDL-cholesterol.50 The study included 
2838 patients aged 40 to 75 years who were randomized to 
placebo (n = 1410) or atorvastatin 10 mg daily (n = 1428). 
It was conducted at 132 centers throughout the UK and Ireland. 
Study participants had no prior history of CHD, abnormally 
high LDL-cholesterol level, retinopathy, albuminuria, tobacco 
abuse, or hypertension. Primary endpoints included time to 
first occurrence of acute coronary events, coronary revascu-
larization, or stroke. The CARDS trial was terminated 2 years 
earlier than expected because of the strongly positively result, 
ie, higher efficacy in the atorvastatin-treated patients. At the 
median duration of follow-up of 3.9 years, at least one major 
cardiovascular event occurred in 127 patients receiving placebo 
(2.46 per 100 person-years at risk) versus 83 who received 
atorvastatin (1.54 per 100 person-years at risk) with rate 
reduction of 37% (95% CI –52 to –17, p = 0.001). Treatment 
would be expected to prevent at least 37 major vascular events 
per 1000 patients over 4 years. Acute coronary heart disease 
events were reduced by 36% (−55 to −9), coronary revascular-
izations by 31% (−59 to 16), and stroke by 48% (−69 to −11). 
Atorvastatin reduced the overall mortality by 27% (−48 to 1, 
p = 0.059). Adverse event rates were not statistically differ-
ent in the atorvastatin group compared with placebo. In other 
words, in patients with type 2 diabetes without elevated baseline 
LDL-cholesterol, atorvastatin 10 mg daily was found to be 
safe and effective in reducing the risk of first cardiovascular 
events and stroke,. These data strongly support the fact that all 
diabetics should receive statin treatment irrespective of their 
LDL-cholesterol concentration.
Metabolic syndrome (MS)
Over the past decade abundant evidence has accumulated 
to the fact that presence of metabolic syndrome signifi-
cantly predicts the cardiovascular events, and has become 
an important prognostic factor. MS, unlike individual risk 
factors, is an interesting combination of related risk factors. 
It is generally described as a multiplex risk factor that 
essentially encompasses a synergistic clustering of a number 
of several cardiovascular risk factors that in many ways are 
interrelated and highly predictive of future events.10–15 The 
organizations, such as the NCEP-ATP and the International 
Diabetes Federation (IDF), have defined MS as a condition 
that includes coexistence of at least three of the following 
five risk factors: (1) hypertension, (2) hyperglycemia, 
(3) hypertriglyceridemia, (4) hypo-alphalipoproteinemia, 
and (5) increased waist circumference as surrogate for central 
obesity (men 40 inches [100 cm]; women 35 inches 
[90 cm]).3,4,17 The third report of the NCEP-ATP, in 2001, 
emphasized the importance of  treating metabolic risk factors 
as the next target second only to the primary target, ie, 
LDL-cholesterol.4 These guidelines were updated in 2004 
when NCEP added an optional LDL-cholesterol goal of less 
than 70 mg/dL in high risk patients, including patients who 
present with AMI or ACS. This stricter goal is now being 
considered as the new target level for LDL-cholesterol for 
the patients with established CHD who have associated high 
risk co-morbidities, such as MS.3 These suggestions are 
consistent with the guidelines on prevention of cardiovas-
cular disease already published by the Joint British Societies 
(desired LDL-cholesterol  80 mg/dL) and the secondary Vascular Health and Risk Management 2009:5 500
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prevention guidelines of the American Heart Association 
(AHA) and American College of Cardiology (ACC) 
sanctioned by the NHLBI (LDL-cholesterol  70 mg/dL 
considered desirable).18
The agreement among various international guidelines 
for CHD risk reduction emphasizing the fact that the various 
risk factors need to be considered together as a multi-factorial 
risk-complex for prognostic as well as for therapeutic purposes 
is on the increase. The knowledge that MS is a significantly 
predictive and relatively treatable multi-factorial risk factor 
for heart disease is now becoming more commonplace.19–20 
Recently, in a joint statement, the ADA and the AHA reiterated 
the significance of diagnosing and managing the critical set 
of risk factors that constitute MS (pre-diabetes, hypertension, 
dyslipidemia, and obesity) in order to curtail the ballooning 
burden of CHD and diabetes mellitus.21
Notwithstanding the plentiful evidence of the importance 
of MS for predicting cardiovascular events, not many trials 
have looked at the benefits of statin drugs on cardiovascu-
lar morbidity and mortality in persons with MS and CHD. 
A sub-analysis of the TNT trial evaluated whether aggressive 
lowering of LDL-cholesterol with high dose atorvastatin 
provides superior cardiovascular benefit for patients with 
both CHD and MS than the current strategy of mere moderate 
LDL-cholesterol reduction with regular dose atorvastatin.
The sub-analysis of the TNT study looking at the 
patients with and without MS included 5584 patients who 
were randomized to low dose atorvastatin (10 mg per day; 
n = 2820) or high dose atorvastatin (80 mg per day; n = 2764). 
The primary endpoint included the time to first major car-
diovascular event – defined as death from CHD, non-fatal 
non-procedure-related MI, resuscitated cardiac arrest, or fatal 
or non-fatal stroke. In the patients with CHD and MS, mean 
on-treatment LDL-cholesterol concentrations at 3 months were 
99.3 mg/dL with low dose atorvastatin, and 72.6 mg/dL with 
high-dose atorvastatin. At a median follow-up of 4.9 years, 
major cardiovascular events occurred in 13% patients receiving 
atorvastatin 10 mg, compared with 9.5% receiving atorvastatin 
80 mg (HR 0.71; 95% CI 0.61–0.84; p  0.0001). Irrespective 
of treatment assignment, significantly more patients with MS 
(11.3%) had a major cardiovascular event than those without 
MS (8⋅0%; HR1.44; 95% CI 1.26–1.64; p  0.0001). This 
increased risk was significantly reduced by 29% in those 
on intensive therapy with atorvastatin 80 mg beyond that 
achieved with regular dose atorvastatin 10 mg (Table 2). 
Statistically significant differences between the groups in 
favor of high dose atorvastatin 80 mg were also seen for the 
secondary end points, such as time to any cardiovascular event 
(0.78, 0.71–0.85; p  0⋅0001), major coronary event (0.72, 
0.60–0.86; p = 0⋅0004), any coronary even (0.75, 0.67–0⋅83; 
p  0⋅0001), cerebrovascular event (0.74, 0.59–0.93; p = 0⋅011), 
and hospitalization for CHF (0.73, 0.55–0.96; p = 0⋅027). There 
was no significant difference between the two treatments for 
all-cause mortality. In the subgroup of MS patients without 
diabetes, while only 8.2% persons receiving atorvastatin 
80 mg had a primary event, a much larger number, ie, 11.6% 
receiving atorvastatin 10 mg, experienced the primary event. 
These findings represent a 30% relative reduction in the risk of 
a major cardiovascular event in favor of the high dose atorvas-
tatin subset (0.70, 0.57–0.84; p = 0.0002). One of the important 
facts is that there exists a 44% greater absolute risk in CHD 
patients with MS than in the CHD patients without MS. This 
fact adds justification and provides a particularly compelling 
rationale for more intensive LDL-lowering therapy in CHD 
patients with MS.22
Aggressive therapy with high dose atorvastatin seems to be 
safe as well. The adverse events rate elated to treatment was 
similar between the two groups. A total of 153 patients (5.4%) 
assigned to atorvastatin 10 mg discontinued the drug because of 
adverse events related to treatment compared with 178 patients 
(6.4%) randomly assigned atorvastatin 80 mg (not statistically 
significant). Persistent elevations in liver enzymes greater than 
three times the upper limit of normal (3 × ULN) obtained a week 
apart were reported in 0.2% of patients receiving atorvastatin 
10 mg and 1.1% of those receiving atorvastatin 80 mg. None 
of the patients a exhibited persistent rise in the concentration 
of creatine phosphokinase (CPK) or rhabdomyolysis.
There are, though, a few limitations to the extrapolation of 
these results from the TNT study. First, the study enrolled only 
those with clinically evident CHD. Thus, the added benefits of 
treating patients with MS beyond the current LDL-cholesterol 
goal of under 100 mg/dL may not be extrapolated to the MS 
patients without CHD.20 Second, there is yet no universally 
accepted definition of MS. Although waist circumference 
might be more closely linked to cardiovascular risk factors 
Table 2 Cardiovascular events in patients with metabolic syndrome 
at various doses of atorvastatin
Low dose 
atorvastatin
High dose 
atorvastatin
n 2820 2764
Major cardiovascular 
events (%)
13.0% 9.5%
Hazard ratio – 0.71
95% confidence interval – 0.61–0.84
p – 0.0001Vascular Health and Risk Management 2009:5 501
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than body-mass index (BMI), the two parameters are closely 
correlated. Generally, a BMI  28 in men has shown close 
agreement with obesity prevalence estimated by using waist 
circumference.24,25 For this reason, the MS subset of the TNT 
study was also analyzed with a definition of MS incorporating 
a BMI  30, but no differences were seen in the outcome. In 
the 4S study, a standard dose of simvastatin (20 or 40 mg) was 
compared with placebo in patients with established CHD.27 
A post-hoc analysis showed that patients with MS benefited 
from simvastatin therapy by at least as much as those without 
MS. It should be noted that the MS patients entered 4S with a 
mean LDL-cholesterol of 190 mg/dL, which was reduced to 
around 120 mg/dL by simvastatin therapy. By contrast, in the 
TNT study, MS patients entered the double-blind treatment 
phase with a mean LDL-cholesterol of 98 mg/dL, represent-
ing a normal baseline LDL-cholesterol level. An aggressive 
atorvastatin therapy regimen further reduced LDL-cholesterol 
to 73 mg/dL, and it was correlated with additional significant 
clinical benefit.
There has been some debate on the strategic importance 
of MS in clinical practice.23 The TNT study clearly shows 
that the relative risk for major cardiovascular events rises 
as the number of components of MS increase, particularly 
when three or more synergistically cluster together. The 
latter essentially constitutes the definition of MS.3,17 The 
patients with MS and CHD in the TNT study were at greater 
risk at baseline than those without. Thus, despite a similar 
drop in the relative risk with statin therapy in patients with 
and without MS, the absolute benefit was greater in those 
with MS because of their higher baseline absolute risk than 
those without MS. In conclusion, the TNT study provides the 
much-needed evidence that patients with CHD and MS are 
good candidates for aggressive lipid-lowering therapy with 
statins.3,19 It is even more important if they also have DM.
Chronic kidney disease (CKD)
Patients with CKD are at increased risk for adverse cardiovascu-
lar outcomes. In the past several years, a significant amount of 
data has been published suggesting that CKD is also one of the 
CHD-disease equivalent conditions. In the US, about 8 million 
individuals carry a diagnosis of CKD of at least stage III severity 
(a glomerular filtration rate [GFR] of  60 mL/min/1.73 m2).44 
Furthermore, approximately 500,000 Americans have end-stage 
renal disease. The elevated risk of cardiovascular mortality 
and morbidity in patients with advanced CKD is already 
well known. Studies over the past decade have given further 
evidence that the renal dysfunction is a significant indepen-
dent predictor of CHD including the patients with just mild 
renal insufficiency.45 Subgroup analyses of several recent 
randomized studies show that statins may have a protective 
effect on renal function.46 In the Heart Protection Study, involv-
ing 15,696 patients with CHD, peripheral arterial disease, or 
DM, randomization to simvastatin 40 mg/day was associated 
with a smaller fall in the estimated GFR (eGFR) compared 
with placebo after an average follow-up of 4.6 years.47 In the 
Cholesterol And Recurrent Events (CARE) study in the patients 
with hyperlipidemia and previous AMI, pravastatin 40 mg daily 
led to a significant protection manifested by the reduction in the 
rate of decline of eGFR among subjects with baseline chronic 
renal insufficiency (eGFR of  40 mL/min/1.73 m2) compared 
with placebo. Furthermore, in the Aggressive Lipid-Lowering 
Initiation Abates New Cardiac Events (ALLIANCE) study, a 
strategy of aggressive atorvastatin treatment led to the preven-
tion of the otherwise anticipated decline in the renal function 
over the 4 years of follow-up, and it tended to modify or slow 
the progression of CKD compared with usual care.48 The safety 
data for atorvastatin in CKD patients are also acceptable. In 
both primary and secondary cardiovascular prevention trials, 
atorvastatin has been shown to reduce the CHD risk without 
any significant safety concerns.1,35,49,50
The subgroup analysis of the TNT study further evalu-
ated the renoprotective effect with higher dose atorvastatin 
treatment to see whether such an effect was graded and 
dose-dependent. eGFR using the Modification of Diet in 
Renal Disease (MDRD) equation was compared at baseline 
and at the end of follow-up. Mean eGFR at baseline was 
65.6 ± 11.4 mL/min/1.73 m2 in the atorvastatin 10 mg group 
and 65.0 ± 11.2 mL/min/1.73 m2 in the atorvastatin 80 mg 
group. At the end of follow-up, mean eGFR increased by 
5.2 ± 0.14 mL/min/1.73 m2 in the atorvastatin 80 mg group 
as compared with only modest 3.5 ± 0.14 mL/min/1.73 m2 
increase in the atorvastatin 10 mg group representing the 
increases of 8.3% and 5.6%, respectively (p  0.0001). 
In the high dose atorvastatin cohort, eGFR improved 
to 60 mL/min/1.73 m2 in significantly more subjects 
(45.6% vs 37.8%) and declined to 60 mL/min/1.73 m2 
in significantly fewer subjects (6.6% vs 9.2%) than in the 
low dose atorvastatin cohort. Among the participants with 
a baseline eGFR  60 mL/min/1.73 m2, significantly fewer 
subjects showed a decline to 60 mL/min/1.73 m2 in the 
atorvastatin 80 mg group than in the atorvastatin 10 mg group 
(6.6% vs 9.2% (p  0.0001) (Table 3). Furthermore, out of 
those patients with a baseline eGFR  60 mL/min/1.73 m2, 
significantly more in the high dose atorvastatin group 
improved to 60 mL/min/1.73 m2 at the end of the study 
than in the lowdose atorvastatin group (45.6% vs 37.8%; Vascular Health and Risk Management 2009:5 502
Singh and Deedwania Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
p = 0.0001) (Table 3). Among the participants who already 
had a diagnosis of CKD at baseline (eGFR  60 mL/min/
1.73 m2), 80 (5.3%) assigned to atorvastatin 10 mg and 
54 (3.4%) assigned to atorvastatin 80 mg experienced a 
decline in eGFR of 25% or greater (p = 0.0077). The TNT 
study essentially exhibited significant cardiovascular benefits 
of aggressive LDL-cholesterol lowering to the new low 
targets that are below the current target recommended by 
the guidelines.27 The analysis among patients with impaired 
renal function demonstrated that in addition to the cardiac 
effects, the benefits of an aggressive atorvastatin treatment 
strategy extended to significant improvement in the renal 
function with high dose statin therapy over that achieved 
with low dose atorvastatin treatment regimen. The expected 
decline in renal function was eliminated over the 5 years of 
the TNT study. It should, however, be noted that the absence 
of an untreated control arm is an acknowledged limitation 
of the TNT trial. Nonetheless, such renoprotective effects 
are of particular importance in patients with GFR  60 mL/
min/1.73 m2 who, with additional loss of renal function, are 
at significantly greater risk for future cardiovascular events.45 
The observation that eGFR showed an improvement in the 
TNT study appears to have been related to the aggressiveness 
of the statin therapy. These data demonstrating renal benefits 
with high dose atorvastatin over those achieved with low dose 
atorvastatin add to the growing evidence base for non-cardiac 
benefits (pleotropic effects) of statins. Although the mecha-
nisms responsible for nephroprotection with statins have yet 
to be defined, the strategy of lowering LDL-cholesterol levels 
to well below 100 mg/dL with high dose atorvastatin appears 
to maximize renal benefits in high risk patients with CHD, 
and is indicated even in the patients with moderate CKD. 
There were no unexpected safety concerns identified even in 
the high dose atorvastatin arm. Equivalent rates of adverse 
events were seen in each of the treatment groups (p = ns). 
The percentage of participants who had persistent elevations 
in liver function enzymes (two measurements of ALT and/or 
AST  3 × ULN obtained a week apart) was numerically 
larger in the atorvastatin 80 mg group than in the atorvas-
tatin 10 mg group, but was generally low and similar to that 
observed in the overall TNT population for both participants 
with CKD (1.4% vs 0.1%) and those with normal eGFR (1.2% 
vs 0.2%). No subject had clinically persistent elevated CPK 
values (two measurements of CPK  10 × ULN).
Cerebro-vascular disease (C-VD)
Atherosclerosis is a systemic disease, and statin therapy 
benefits atherosclerosis as a whole. Several clinical trials 
involving the use of statins have demonstrated that lowering 
cholesterol with statins reduces the risk of stroke as well 
as providing cardiac benefits in patients with CHD or 
even in those without manifest CHD, but with presence 
of major risk factors. A meta-analysis of 26 trials showed 
a relative risk reduction of 21% for all varieties of stroke 
without significant increase in hemorrhagic stroke. Fatal 
strokes were reduced by 9%. The statin effect was closely 
associated with a reduction in LDL-cholesterol. Each 10% 
reduction in LDL-cholesterol decreased the risk of all strokes 
by 13.2%.
Currently, in patients with ischemic stroke but no 
prior history of a coronary event, no clear recommenda-
tion for use of statins has been available, even though 
such patients make up 80% of the stroke population. 
A recent study, the SPARCL study, was the first study 
that set out to evaluate prospectively the effects of statin 
therapy in patients who previously had a stroke or TIA 
and who had no known CHD.52 The main entry cri-
teria for men and women included the following: (i) 
Previously documented stroke (ischemic or hemorrhagic) 
or TIA, 1 to 6 months before randomization, (ii) LDL-
cholesterol  100 mg/dL and 190 mg/dL, and (iii) 
Modified Rankin score 3 (ie, functionally independent). 
Patients were excluded if they already had a history of 
CHD, significant peripheral vascular disease, atrial fibril-
lation, prosthetic heart valve, clinically significant mitral 
stenosis, sinus node dysfunction, uncontrolled hyperten-
sion, stroke caused by a revascularization procedure or 
trauma, subarachnoid hemorrhage, or liver or renal disease. 
A total of 4731 patients were enrolled into the trial. The 
mean age (approximately 62.5 years) and male/female ratio 
(60%/40%) meant that the SPARCL patients were more 
representative of the true stroke population, with a substan-
tially higher percentage of women and a mean age approxi-
mately 5 years older than the populations of major CHD 
statin trials. Approximately 20% of the SPARCL patients 
were current smokers, 62% were hypertensive, 16% had 
Table 3 Percentage of patients with decline or improvement from 
baseline eGFR
Low dose 
atorvastatin
High dose 
atorvastatin
p
Decline in eGFR 9.2% 6.6% 0.0001
improvement in eGFR 37.8% 45.6% 0.0001
Notes: Decline signifies a baseline estimated glomerular filtration rate (eGFR) 
60 mL/min/1.73 m2 and a last visit eGFR  60 mL/min/1.73 m2; improvement signifies 
a baseline eGFR  60 and a last visit eGFR 60 mL/min/1.73 m2.Vascular Health and Risk Management 2009:5 503
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diabetes, and 20% had carotid stenosis. Thirty percent 
of the patients had history of prior TIA and 70% a prior 
stroke, of which about 3% were hemorrhagic. Within 30 
days of initial screening, patients were randomized to 
receive either atorvastatin 80 mg/day (2365 patients) or 
placebo (2366 patients). The patients were followed for 
a mean of 4.9 years (maximum 6.6 years). The average 
baseline LDL-cholesterol was 133 mg/dL, which fell by 
38% in the atorvastatin group over the average 4.4-year 
follow-up, versus a 7% fall in the placebo group. This 
appeared to translate into a significant reduction in the 
primary end point of recurrent stroke, with an adjusted 
hazard ratio of 0.84 in the atorvastatin group. The treated 
group also showed significant reductions in fatal stroke and 
ischemic stroke and there was a trend toward fewer non-
fatal strokes. There was, however, a significant increase 
in the rate of hemorrhagic stroke. The number of patients 
who need to be treated for 5 years with atorvastatin to 
prevent 1 stroke is 46; to prevent 1 major cardiovascular 
event, 29; and to prevent 1 revascularization procedure, 
32. Despite the slight increase in the incidence of hemor-
rhagic stroke in the treatment cohort, the benefit versus 
risk ratio favored atorvastatin for stroke reduction (11.2% 
vs 13.1%, respectively, p = 0.03), as well as for stroke 
plus major coronary events reduction (14.1% vs 17.2%, 
p = 0.002). These data, thus, clearly support the recom-
mendation that atorvastatin 80 mg/day should be started 
in all patients with stroke or TIA soon after the episode 
for future risk reduction.
Congestive heart failure (CHF)
CHF constitutes another high risk group of patients. It 
should be noted that CHF is the only cardiac diagnosis for 
which the incidence as well as prevalence has been on the 
rise. This may be a reflection of better treatment of acute 
events, the survivors of which may be at a greater risk of 
developing a chronic disabling condition such as CHF. 
Statins have been shown to reduce cardiovascular events 
in patients with and without known CHD in many random-
ized clinical trials. Patients with CHF were usually not 
included in these trials. It should also be noted that CHD 
and CHF commonly coexist, as described above. Recently, 
a few randomized trials have ventured to address this issue. 
Some older observations have shown that statins have a 
potential benefit in the treatment for CHF. As we know, 
CHF is a pathophysiologic condition commonly driven by 
neuro-hormonal activation, inflammation, and endothelial 
dysfunction. In small studies, statins have been shown to 
improve endothelial function2 and to lower plasma levels 
of pro-inflammatory cytokines in patients with CHD who 
also have dyslipidemia. Statins generally have multiple 
pleotropic effects including antihypertrophic, antioxidant, 
and antifibrotic influences on the myocardium. Thus, 
they may affect immune function, macrophage metabo-
lism, and cell proliferation independently of changes in 
LDL-cholesterol concentration.16,37,38 In addition, by pre-
venting recurrent ischemia in patients with CHD, statins 
may prevent the development or deterioration of CHF. On 
the other hand, there are valid concerns about the fact that 
statins may cause higher rates of adverse effects in such 
patients.39 Some observational studies have indicated that 
there exists an association between low cholesterol levels 
and adverse outcomes in advanced CHF, and lowering the 
levels too low may be deleterious.40 It has been suggested 
that the decrease in ubiquinone levels caused by statin 
therapy may be responsible for these deleterious conse-
quences because ubiquinone is a potential antioxidant and 
CHF is a condition of pro-oxidant stress.41 The TNT trial 
was the first randomized clinical trial to demonstrate the 
benefits of aggressive LDL-cholesterol lowering in patients 
with CHD. The intensive treatment regimen consisted of 
a high dose’regimen (80 mg daily of atorvastatin), which 
was compared with a low dose regimen (10 mg atorvastatin 
daily) in 10,001 patients with the diagnosis of stable CHD, 
defined as prior MI, prior or current angina with evidence 
of coronary artery disease, or prior history of coronary 
revascularization. Patients with advanced heart failure 
(New York Heart Association [NYHA] class IIIb or IV or 
left ventricular ejection fraction 30%) were excluded 
from the trial. Over a mean follow-up of 4.9 years, the high 
dose of atorvastatin lowered LDL-cholesterol to a mean 
of ∼77 mg/dL vs a mean of ∼101 mg/dL with the low dose. 
This additional more aggressive drop in LDL-cholesterol 
levels lowered the risk for a major cardiovascular event, 
the primary end point of the trial, by 22% compared with 
the low dose regimen. One of the predefined secondary end 
points, hospitalization for CHF, occurred in 2.4% of the 
80 mg dose group compared with 3.3% of the 10 mg dose 
group – a relative risk reduction of 26% (HR 0.74, 95% CI 
0.59–0.94, p  0.012) (Figure 1). These findings add to the 
increasing evidence of benefit with statins in the treatment 
of patients with CHF.
Even though the patients with advanced CHF were not 
included in the TNT trial, 7.5% of the high dose group and 
8.1% of the low dose group had a history of CHF at base-
line (self-reported). When the TNT patients were divided Vascular Health and Risk Management 2009:5 504
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into those with or without history of CHF, the effect of 
the high dose statin on CHF hospitalization became even 
more marked in the patients reporting a history of CHF at 
baseline. These patients showed a 41% reduction in risk 
compared with a 13% reduction in hospitalizations in the 
group without a history of CHF. Compared with patients 
with no CHF hospitalizations, those who were hospitalized 
with CHF during the trial had lower rates of beta-blocker 
(45.1% vs 54.0%) and aspirin (74.1% vs 86.9%) use at 
baseline and higher rates of angiotensin-converting enzyme 
inhibitor (50.3% vs 26.5%), angiotensin receptor blocker 
(10.5% vs 5.1%), aldosterone antagonist (1.4% vs 0.3%), 
and diuretic use (50.3% vs 13.3%). The benefit did not 
appear to be mediated by a reduction in preceding isch-
emic events in most cases and appeared to be related to 
the degree of LDL-cholesterol lowering. There was a 0.6% 
reduction in risk of CHF hospitalization for each 1 mg/dL 
(0.259 mmol/L) reduction in LDL-cholesterol (p = 0.007). 
Regardless of the statistical correlation with lower LDL-
cholesterol in the high dose group, however, it appears 
that the benefit on CHF hospitalization is not only due 
to LDL-cholesterol lowering but also due to some other 
pleotropic effects of atorvastatin. Furthermore, aggressive 
therapy with atorvastatin even in patients with stable CHD 
significantly reduces subsequent hospitalizations for CHF 
compared with regular less aggressive therapy. This benefit 
was most pronounced in patients with a baseline history 
of CHF. Also, the CHF hospitalizations were not usually 
preceded by an ischemic coronary event, suggesting that 
the 80 mg atorvastatin therapy may confer increased benefit 
through other mechanisms as yet undefined.
Pre-percutaneous intervention 
(pre-PCI) patients
Patients who are going to undergo PCI, especially those 
who present with ACS, clearly appear to have lower recur-
rent cardiovascular events with intensive statin therapy as 
demonstrated by the PROVE-IT trial. Furthermore, patients 
with stable and unstable coronary syndromes do better if 
pre-treated with high dose statins prior to PCI as shown 
in the Atorvastatin for Reduction of Myocardial Damage 
during Angioplasty (ARMYDA)55 and ARMYDA-ACS56 
trials. In the ARMYDA trial, 153 patients with stable 
CHD and chronic stable angina were enrolled and were 
pre-treted with atorvastatin 40 mg/day for 7 days prior to 
PCI. This strategy significantly reduced ‘procedural’ myo-
cardial injury in such patients undergoing elective coronary 
intervention. Post-procedural peak levels of troponin-I 
were 0.09 ± 0.2 vs 0.47 ± 0.13 for patients with and without 
atorvastatin pre-treatment respectively (p = 0.0008). In the 
Atorvastatin for Reduction of Myocardial Damage During 
Angioplasty-Acute Coronary Syndromes (ARMYDA-
ACS) trial, patients were randomized in a double-blind 
manner to pretreatment with atorvastatin (80 mg 12 hours 
prior to PCI and 40 mg immediately pre-PCI; n = 86) or 
matching placebo (n = 85). After the procedure, all patients 
were treated with atorvastatin 40 mg indefinitely. Blood 
samples for biomarker evaluation were drawn immediately 
pre-PCI and at 8 and 24 hours post-PCI. Among patients 
with ACS undergoing PCI, pretreatment with atorvastatin 
80 mg was associated with a reduction in major adverse 
cardiac events at 30 days compared with placebo, driven 
exclusively by a reduction in periprocedural MI. Results 
of the present study are similar to the original ARMYDA 
study, which also showed a reduction in periprocedural 
MI with atorvastatin pretreatment but in a low-risk, stable 
angina, elective PCI population. When feasible, treat-
ment with a loading dose of atorvastatin pre-PCI appears 
promising. In another study, Herrmann et al stratified 
296 consecutive patients who were undergoing stenting of 
a de novo stenosis according to the pre-procedural status of 
statin therapy (229 statin-treated and 67 control patients). 
Incidence of periprocedural myocardial injury was assessed 
by analysis of creatine kinase (CK; ULN 70 IU/L for 
women, 80 IU/L for men) and cardiac troponin T (cTnT; 
bedside test; threshold 0.1 ng/mL) before and 6, 12, and 
24 hours after the intervention. Relative to control patients, 
the incidence of CK elevation 3 × ULN was more than 
90% lower in statin-treated patients (0.4% vs 6.0%, 
p = 0.01). Statin therapy was the only factor independently 
associated with a lower risk of CK elevation 3 × ULN 
(odds ratio 0.08, 95% CI 0.01–0.75; p = 0.03). The overall 
incidences of CK and cardiac troponin T elevation were 
slightly lower in statin-treated than in control patients 
(14.4% vs 20.9%, p = 0.3, and 17.9% vs 22.4%, p = 0.5, 
respectively). Therefore, pre-procedural statin therapy 
was demonstrated to reduce the incidence of larger-sized, 
post-PCI MI.57
Newer trials of statin therapy 
in high risk patients
The strategy of aggressive lipid lowering with high dose 
statins in patients with high risk of CHD appears to be 
gaining momentum. These suggestions are also supported 
by data from morphological studies, such as REVERSAL 
and the Study To Evaluate the Effect of Rosuvastatin on Vascular Health and Risk Management 2009:5 505
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Intravascular Ultrasound-Derived Coronary Atheroma 
Burden (ASTEROID), which used high doses of potent 
statins, ie, atorvastatin and rosuvastatin respectively. 
The REVERSing Atherosclerosis with Aggressive Lipid 
Lowering (REVERSAL) study measured changes in ather-
oma burden as assessed by intravascular ultrasound (IVUS) 
in 654 patients aged 35 to 78 years with symptomatic CHD 
and at least 20% stenosis by coronary angiography. Base-
line LDL-cholesterol was between 125 and 210 mg/dL after 
an 8-week washout period. Patients were randomized to 
moderate lipid lowering with pravastatin 40 mg or inten-
sive lipid lowering with atorvastatin 80 mg for 18 months. 
By the end of the treatment period, LDL-cholesterol was 
significantly lower among patients who had received 
atorvastatin compared with those on pravastatin. The 
primary prespecified endpoint of the trial was change 
in IVUS-determined atheroma volume, which showed a 
significant increase in the pravastatin arm compared with 
baseline (progression), versus no overall change (absence 
of increase) in atheroma volume in patients in the ator-
vastatin arm. An unpaired comparison of the treatment 
arms showed a significant difference in progression rate 
(p = 0.02). Although no net regression of atheroma was 
found for the atorvastatin group, individual patients in this 
group experienced significant regression.53 The intensive 
statin therapy regimen was also tested in ASTEROID. The 
treatment group similarly showed significant regression of 
atherosclerosis as measured by IVUS.54
Conclusion
CVD continues to be the leading cause of mortality and 
morbidity. Over the past several years, although the strategy 
of aggressively lowering the LDL-cholesterol with statins 
has significantly decreased cardiac events, an unacceptable 
number of CVD events still occur in treated patients, as 
is apparent from the majority of the studies of aggressive 
versus standard statin therapy. This is especially true for 
the patients who are generally classified as being high risk. 
The data from several of the randomized trials now strongly 
favor the use of high dose atorvastatin, and recommend 
aggressive versus usual LDL-cholesterol reduction as part 
of new strategy for the CHD patients as well as those with 
various CHD risk-equivalent conditions such as DM, MS, 
CKD and peripheral/cerebrovascular disease, as well as 
those who are pre-PCI.
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